Stephen P. Carey, serving as the Senior Vice President and Chief Financial Officer for ANI Pharmaceuticals Inc. (NASDAQ:ANIP), completed a significant equity transaction on June 5, 2026. The executive disposed of 3,312 shares of the company's common stock on that date. The total value realized from this sale was $264,960, calculated based on a share price of $80.00.
According to regulatory filings, this sale was not an isolated event but followed a simultaneous acquisition of an identical number of shares on the same day. Carey obtained these 3,312 shares through the exercise of stock options. The acquisition cost for these shares was $163,977, derived from an exercise price of $49.51 per share. The spread between the exercise price and the sale price represents the financial mechanics of the transaction.
Both the option exercise and the subsequent sale were facilitated under a Rule 10b5-1 trading plan. This pre-arranged framework was adopted by Mr. Carey on March 6, 2026. The stock options that were exercised had a vesting schedule tied to annual increments of 25%, commencing from March 31, 2018, and continuing through March 31, 2021. These specific options are scheduled to expire on March 30, 2027.
Following the completion of these transactions, Mr. Carey's direct holdings in ANI Pharmaceuticals include 180,393 shares of common stock. Additionally, he retains 6,626 stock options. This data point provides a snapshot of his current equity exposure to the company.
The transaction occurs while ANI Pharmaceuticals is trading at $81.20 per share. The company's market capitalization stands at $1.73 billion. Current valuation metrics show a price-to-earnings (P/E) ratio of 20.86. According to analysis from InvestingPro, the stock is currently trading below its calculated Fair Value of $97.42, suggesting potential undervaluation relative to internal models.
Financial performance metrics over the last twelve months show a return on equity of 17%. The company remains profitable, with net income projections indicating growth for the current year. This financial health is reinforced by the recent first-quarter 2026 results, which significantly exceeded market expectations.
ANI Pharmaceuticals reported an earnings per share (EPS) of $2.05 for Q1 2026. This figure represents a 41.38% increase over the analyst forecast of $1.45. Revenue for the quarter reached $237.5 million, surpassing the projected $213.42 million. These results have been received positively by investors, reflecting effective strategic execution in the current market environment.
There are currently no updates regarding mergers or acquisitions for the company. Analyst firms have not recently adjusted their ratings for ANI Pharmaceuticals, maintaining their current assessments. The company's financial achievements highlight its position within the pharmaceutical sector, where consistent earnings growth and revenue expansion are critical indicators of stability and operational efficiency.